Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.58 |
| ▸ | CASR | P41180 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | AGXT | P21549 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25297052 | 1.00 | TAAR1 (0.58) | TAAR1CASRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6444198 | 0.90 | TAAR1 (0.68) | TAAR1CASRCYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL10671127 | 0.89 | TAAR1 (0.66) | TAAR1CASRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL12706128 | 0.85 | TAAR1 (0.56) | TAAR1CASRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL27993059 | 0.83 | CASR (0.59) | TAAR1CASRMTNR1AMTNR1BMAOB | |
| SCHEMBL4243808 | 0.83 | TACR1 (0.63) | TAAR1CASRMAOBKMT2ASMN1; SMN2 | |
| SCHEMBL4748456 | 0.83 | CYP1A2 (0.51) | TAAR1CASRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL28893947 | 0.82 | SLC6A2 (0.56) | TAAR1CYP1A2CYP2D6KMT2ASMN1; SMN2 | |
| SCHEMBL12706140 | 0.82 | TAAR1 (0.60) | TAAR1CYP1A2CYP2D6CYP2C19MAOB | |
| SCHEMBL2368100 | 0.81 | CYP1A2 (0.83) | TAAR1CYP1A2CYP2D6CYP2C19SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2018364-B1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-7709507-B2 | Therapeutic fluoroethyl ureas | ALLERGAN, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20070270498-A1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN, INC. | 2007-11-22 | — | — | US | disclosed |
| EP-0659737-B1 | Catecholamine surrogates useful as beta 3 agonists | BRISTOL MYERS SQUIBB CO (US) | 2003-03-26 | — | — | EP | disclosed |
| US-5776983-A | ANTIDIABETIC AGENTS, OBESITY, GASTROINTESTINAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-07 | — | — | US | disclosed |
| EP-0659737-A2 | Catecholamine surrogates useful as B3 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270498-A1 | THERAPEUTIC FLUOROETHYL UREAS | SLC14A1, MAPT, UTS2R | TAAR1 2600/4885CASR 4167/4885CYP1A2 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.